Anthracycline cardiotoxicity remains a dose-dependent limitation of chemotherapy, with recent advances improving the comprehension of its molecular mechanisms, prevention, and treatment.
Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. In this review, we discuss the incidence, risk factors, types, and pathophysiology of anthracycline cardiotoxicity, as well as methods to prevent and treat this condition. We also summarize and discuss advances made in the last decade in the comprehension of the molecular mechanisms underlying the pathology.
Sawicki et al. (Tue,) conducted a review in Anthracycline cardiotoxicity. Anthracycline cardiotoxicity remains a dose-dependent limitation of chemotherapy, with recent advances improving the comprehension of its molecular mechanisms, prevention, and treatment.